Background: An ability to predict the response to conventional non-surgical treatment of a periodontal site would be advantageous. However, biomarkers or tests devised to achieve this have lacked sensitivity. The aim of this study is to assess the ability of a novel combination of biomarkers to predict treatment outcome of patients with chronic periodontitis.
A lthough diagnosis of periodontal disease per se is well established, with easy-to-use and relatively non-invasive procedures, there are a number of limitations. Specifically, an ability to predict response to treatment or the likelihood of future tissue breakdown is absent. [1] [2] [3] Thus, there is a need for alternative diagnostic approaches that could be applied at initial triage and be used further to direct treatmentplanning regimens. One approach is the use of biomarkers. 3, 4 Various molecular biomarkers for periodontitis have been examined, [5] [6] [7] particularly in saliva, plaque, and gingival crevicular fluid (GCF). Although focus has been on GCF constituents, 8, 9 most of the tests devised thus far have lacked sensitivity. This is likely due to the complex nature of periodontitis such that a single parameter is unlikely to be sufficiently discriminating. 10, 11 A previous pilot study reported that a combination of high levels of three GCF enzymes, prior to treatment, provided a predictive value of the outcome of conventional non-surgical treatment of 88%, compared with 61% for each enzyme alone. 12 Biomarkers were easily assayed and were representative of inflammation (matrix metalloproteinase [MMP]-8, elastase) and physiologically relevant bacterial community activity (sialidase).
As well as GCF biochemical biomarkers, presence and levels of key bacteria have been used as possible biomarkers of disease. Most attention has been directed at Porphyromonas gingivalis and Tannerella forsythia, members of the ''red complex'' of periodontopathogens, 13, 14 because these bacteria are generally found at higher levels in association with disease. This longitudinal clinical study extends earlier findings using MMP-8, elastase, and sialidase with a larger cohort of patients and determines whether addition of key bacteria to these GCF enzyme activities could provide a profile with enhanced predictive value for the outcome of non-surgical periodontal treatment.
MATERIALS AND METHODS

Patient Population
This prospective study was approved by the North Sheffield Research Ethics Committee, Yorkshire and Humberside, U.K. (study number: 13/YH/0114, May 16, 2013) . Patients attended the Periodontology Clinic in the Charles Clifford Dental Hospital, Sheffield, U.K., between 2013 and 2015. Potential participants were screened by the consultant periodontist (AR). Eightynine patients (44 males and 45 females, aged 30 to 70 years; mean age: 49.7 -8.9 years) participated in the study. Inclusion criteria were as follows: 1) age ‡18 years; 2) ‡20 teeth; and 3) diagnosis of chronic periodontitis (CP) with diseased sites. Three individual sites were chosen at random for study including one deep bleeding (DB; ‡6 mm), one deep non-bleeding (NB; ‡6 mm), and one healthy (£3 mm) site. For the diseased sites, these were the deepest and most accessible sites available. Patient exclusion criteria were as follows: 1) receipt of antibiotics or periodontal treatment in the 3 months preceding the study; 2) pregnancy and lactation; and/or 3) history of systemic disease or medication that may affect the periodontal condition. Patients did not use chlorhexidine. Written informed consent was obtained from individuals entering the study.
Clinical Measures and Periodontal Treatment
Full-mouth clinical parameters of probing depth (PD), plaque index (PI), 15 bleeding on probing (BOP), and clinical attachment level (CAL) were recorded at six sites per tooth. Presence or absence of plaque was identified using a Langer curet. Parameters of PD, CAL, and BOP (within 30 seconds) were obtained using a periodontal probe. † Two dental therapists (Nivan Al-Hammouri and Claire Vallance-Owen, Charles Clifford Dental Hospital, Sheffield, U.K.), who had been internally calibrated, provided standardized non-surgical treatment to manage periodontal condition and also collected full-mouth clinical data. These therapists were masked to clinical measurements recorded in the data capture forms of previous visits to avoid bias. Clinical data and samples were collected at baseline and at 3 and 6 months.
Management included oral hygiene instruction, scaling and root surface debridement under local anesthesia for sites with PD ‡4 mm. Reduction of ‡2 mm in PD from the baseline was taken to indicate that the site had responded to treatment. Sites ‡4 mm were reviewed and retreated 3 and 6 months later, as appropriate.
GCF and Plaque Sample Collection and Analysis
Sites selected for sampling were isolated and dried with cotton wool and protected from salivary and blood contamination. Supragingival plaque was removed, the tooth was air dried, and GCF was collected using paper strips ‡ placed at the entrance of the periodontal crevice for 30 seconds. 4, 16 GCF volumes were immediately determined as described by Griffiths et al. 17 or by weighing when their volume was outside the accurate range of the electronic gingival fluid measuring device § (i.e., >1.7 mL). To recover enzymes from the samples, the paper strips were eluted for 1 hour in 105 mL sterile phosphatebuffered saline (PBS, pH 7.3) containing 1% bovine serum albumin. The samples were centrifuged at 10,000 · g for 15 minutes by centrifugal filtration. i GCF samples were analyzed immediately for concentration of active MMP-8, elastase, and sialidase as described by Gul et al. 12 Subgingival plaque samples were collected with a sterile curet from the same three representative sites at each time point, placed in 500 mL sterile PBS, and stored at -80°C until DNA was extracted and analyzed by 16srRNA quantitative polymerase chain reaction (qPCR) for levels of P. gingivalis, T. forsythia, and Fusobacterium nucleatum (see supplementary Appendix 1 in online Journal of Periodontology). Enzyme and bacterial parameters in all samples were analyzed by a single independent investigator (SG). Similar methodology has been used by others. 18 
Statistical Analyses
All statistical methods used were under the direction of a senior statistician (Rosie Taylor, Statistical Services Unit, University of Sheffield, Sheffield, U.K.). Analysis was undertaken to investigate mean clinical mouth score and individual site scores at each time point to confirm that treatment was successful at most sites for the majority of patients. Subsequent analysis looked at the ability of biomarker values to predict clinical outcome (PD) at 6 months. Only data applying to patients who completed the study were analyzed.
''Continuous'' data were tested for normal distribution and thereafter subjected to appropriate parametric/non-parametric testing (Shapiro-Wilk test). The Kruskal-Wallis test was used to find statistically significant differences in biomarker values in the three selected sites and at each time point. Correlations between clinical measures and biomarker values were evaluated using Spearman correlation. An improvement of ‡2 mm in PD was used to dichotomize the outcome variable at 6 months.
Receiver operating characteristic (ROC) curves were produced for each biomarker, and areas under the curve (AUCs) were used to determine threshold points that produced the highest diagnostic sensitivity and specificity.
To determine whether ''biomarker profile'' is a useful prognostic tool for treatment outcome, logistic regression analysis was performed with baseline continuous values of biomarker levels (as predictors) versus binary outcome measure 6 months after treatment as the dependent variable. Regression analysis with backward stepwise technique was used to exclude redundant biomarkers. 12 All variables included in the final multivariate model were determined to be independent through the assessment of their colinearity. Odds ratio (OR) estimates and 95% confidence intervals (CIs) were calculated and statistical significance was defined as P £0.05. Statistical power was calculated on the basis that 10 patients should be recruited for each of the 10 variables. These variables were: 1) the two types of sites investigated (DB and NB), 2) the three enzymes, 3) the three bacteria, 4) the patient and 5) the change from baseline to 6 months.
For validation against independent data, baseline continuous values of biomarkers from the pilot study 12 were dichotomized using threshold points from this study. Similarly, the current study was reanalyzed using threshold values derived from the pilot study. 12 Logistic regression was used with binary baseline enzyme values using these dichotomized prognostic cut-off points as predictors against binary treatment outcome data. All calculations were performed using a statistical software package. ¶
RESULTS
Patients
A total of 101 patients were invited to join the study; two patients were excluded according to the inclusion/exclusion criteria, two failed to attend further appointments, and eight declined to participate. Of the 89 remaining patients (30% aged 30 to 39 years, 30% aged 40 to 49 years, 20% aged 50 to 59 years, and 20% aged ‡60 years), 83 completed the 3-month review, and 77 completed the full study, of which eight were smokers. No adverse events were reported as a consequence of the study.
Clinical Data
The extent of disease ranged from moderate-tosevere CP as defined by the periodontal disease classification system of 1999. 19 Full-Mouth Data After initial treatment, reductions in PI and BOP were statistically significant, and retreatment at 3 months resulted in further reductions. At baseline, approximately two thirds of sites had PD £3 mm, whereas the remaining sites were almost equally distributed between PD of 4 to 5 and ‡6 mm. At 3 months, mean percentage of sites with PD £3 mm increased, whereas mean percentage of sites with PD ‡6 mm decreased (P <0.001). At 6 months, additional significant improvements were seen, with mean percentage of healthy sites increasing to 82% -11% and mean percentage of sites with PD ‡6 mm decreasing to 3% (P <0.0001).
Diseased Sites Sampled
Of the sites that were sampled, mean PDs at baseline for NB (6.7 -1.1 mm) and DB (6.8 -1.2 mm) sites were not significantly different from each other. At 3 months after initial treatment, mean PDs for both types of sites showed statistically significant decreases (analysis of variance) to 5.3 -1.6 (P = 0.0001) and 5.3 -1.5 mm (P = 0.0001), respectively, and further reductions to 4.4 -1.6 (P = 0.0001) and 4.5 -1.7 mm (P = 0.0001), respectively, were seen after the second treatment phase.
Response to treatment for each DB and NB site that was sampled is shown in Figure 1 and supplementary Figure 1 in online Journal of Periodontology, respectively. At 6 months, 105 sites showed improvement (defined as ‡2 mm improvement in PD), but 48 sites did not respond adequately. These included six NB (8%) and 13 DB (17%) sites that only partially improved (<2 mm), 12 NB (16%) and eight DB (10%) sites that remained unchanged, and five NB (7%) and four DB (5%) sites that deteriorated. Responses were similar among patients who smoked, with 63% of diseased sites (NB and DB) improving by ‡2 mm in PD during the period.
Biomarker Levels
All biomarkers tested revealed significant differences in average levels between diseased and healthy sites, but DB and NB diseased sites at baseline did not differ (see supplementary Table 1 in online Journal of Periodontology). Sites that failed to respond to treatment adequately after 6 months (i.e., <2 mm reduction in PD) generally had higher levels of all biomarkers at baseline (Table 1) . During the treatment period, comparing baseline measures with those at 6 months, all biomarkers showed statistically significant decrease at diseased sites ( Fig. 2 and detailed in supplementary Table 2 the exception of levels of F. nucleatum (see supplementary Table 2 in online Journal of Periodontology).
Threshold Values ROC curves were used to evaluate the ability of biomarkers in GCF and plaque to identify whether the site is diseased or healthy. Threshold points with the highest sensitivity and specificity were selected for each of the biomarkers at baseline (Table 2 and supplementary Fig. 2 in online Journal of Periodontology). Furthermore, values of MMP-8, elastase, sialidase, and levels of P. gingivalis and T. forsythia showed high sensitivity (77% to 86%) and specificity (79% to 86%) and AUCs (0.79 to 0.92) for diagnosis of disease.
Predictive Value
To determine whether biomarker profile is a useful prognostic tool Changes in PD of all DB sites from baseline to 6 months after treatment. Changes in the six biomarkers at all healthy, NB, and DB sites from baseline (B) to 3 (3m) and 6 months (6m) after treatment. Tables  3 and 4 . For all diseased sites, the three enzyme levels together (MMP-8, elastase, sialidase) were able to predict treatment outcome with ‡80% certainty. Bacterial levels alone were able to predict treatment outcome with ‡74% certainty, but when combined with enzyme biomarkers, there was an increase in prediction value to ‡92% (Table 3) . OR and 95% CI of these biomarkers are shown in Table 4 . Backward stepwise logistic regression was used to exclude variables that could not add any significant predictive value to the combination, and it was found that F. nucleatum was a redundant variable (P >0.05), whereas others were not. Furthermore, each individual biomarker alone was not able to predict treatment outcome at a level greater than the null hypothesis (61% in NB and 62.5% in DB sites; Table 3 ).
Validation of the predictive value of the biomarker profile. Threshold levels of GCF enzymes arrived at in this study were used to test their sensitivity and specificity for diagnosis and for prognostic value against an independent dataset. Data used were those reported in the earlier pilot study 12 comprising 22 independent patients. Again, ROC curves were used to identify specificity and sensitivity and logistic regression to determine predictive value but using only GCF enzymes. Diagnostic value of those thresholds was as high for the independent validating patient cohort as it was for patients in this study (see supplementary Table 3 in online Journal of Periodontology). Also, prognostic value of enzyme threshold levels to predict the treatment outcome ( ‡2 mm PD improvement) was as high (84%) for the independent validation patient cohort as it was for patients in this study (>80%) (see supplementary Table 4 in online Journal of Periodontology).
DISCUSSION
The key finding of the present study is that combined high levels of three GCF enzymes and two bacteria provide a good prediction for the outcome of nonsurgical treatment on a site-specific basis. Although it is acknowledged that there are a number of limitations to the use of biomarkers for diagnosing/predicting disease outcome (e.g., appropriate marker selection, validation and robustness of analysis), and these can dramatically affect their predictive value, such limitations can be reduced by using combinations of different biomarkers, each of which alone may not be usefully predictive. Therefore, the rationale for the study was based on the premise that periodontal disease has a multifactorial etiology, and therefore, combinations of host and bacterial biomarkers are more likely to provide useful diagnostic and prognostic information than single biomarkers. Indeed, no individual biomarker has yet been demonstrated to be sufficiently reliable for clinical use. [5] [6] [7] 11 In this study, new and untried biomarkers were not sought out; biomarkers for which there has been clear evidence of association with disease were used. MMP-8 and elastase were selected because they are secreted by neutrophils. 20 Sialidase was selected because it is mainly of bacterial origin and produced by the red complex pathogens P. gingivalis, T. forsythia, and Treponema denticola with evidence that it plays a role in pathogenesis. 21, 22 Furthermore, a pilot study identified increased sialidase in GCF of diseased sites, 12 whereas others detected Tannerella sialidase gene (nanH) at high levels in periodontal plaque RNA. 23 These enzymes have been investigated individually by others in relation to periodontal disease [24] [25] [26] [27] but not in combination. In the present study, assessment of the level of selected key bacterial species that were considered to be etiologically important contributors to CP and their progression as potential biomarkers was included. [28] [29] [30] Although ideally one would conduct a qPCR study of a larger number of bacterial species, for practical reasons (particularly availability of control DNA material) and given their prominence and close association, the present study focuses on P. gingivalis and T. forsythia as representative red complex periodontal pathogens. 14 However, it is acknowledged that ideally T. denticola or Filifactor alocis should have been included. However, F. nucleatum was included as a positive internal control because it would be expected to be present in all samples because it acts as a ''bridging'' species in the oral biofilm. 31, 32 Moreover, plaque samples were collected using curets, which others have shown to yield higher levels of bacterial DNA than paper points. 32, 33 The present study findings strongly suggest that baseline concentrations of active MMP-8, elastase, and sialidase cannot only be used to diagnose a diseased site, but when combined, also predict its likely response to treatment. Enzyme levels correlated with initial PD, and with the exception of sialidase, are in agreement with other information in the literature. [34] [35] [36] [37] [38] To the best of the authors' knowledge, the pilot study was the first to report the predictive value of sialidase in combination, 12 and those data have been upheld in this larger cohort study. In both this and the previous pilot study, 12 ROC curves were used to determine whether a given enzyme level could act as a threshold point to differentiate health from disease. The resultant diagnostic sensitivity and specificity for each enzyme was >78%, which for MMP-8 and elastase is in keeping with some earlier studies. 6, 7, [39] [40] [41] Although these findings for diagnosis are useful, the primary value of a ''biomarker profile'' is whether it is able to predict the outcome of non-surgical periodontal treatment or disease progression. Consequently, the current study looked beyond the diagnostic value of biomarkers and used backward stepwise logistic regression to evaluate the contribution of each biomarker to the predictive value of the biomarker profile. The latter was judged against the primary treatment outcome measure (i.e., improvement of 2 mm in PD 11, 42 ).
These findings expand and improve on recent reports that a raised MMP-8 level is a good predictor of treatment outcome 7, 11, 41 and that elastase might be useful for predicting disease progression. 43, 44 In addition, whereas Beighton et al. 25 showed that sialidase could differentiate between gingivitis and periodontitis, to the best of the authors' knowledge, this is the first study to report correlation of initial GCF sialidase levels with treatment outcome. The mere presence and absence of key bacterial species are not sufficient to distinguish healthy sites from diseased sites, and it is generally accepted that increase in the level of certain species is important. [45] [46] [47] [48] Indeed, proportions of P. gingivalis and T. forsythia above the critical threshold points of 0.23% and 0.35%, respectively, were associated with disease (sensitivities and specificities >77%). In terms of response to treatment, although there is much data indicating that levels of T. forsythia and P. gingivalis at diseased sites reduce during treatment, there is a shortage of data on the usefulness of these bacteria as prognostic tools; the current study contributes to filling this research gap. Using logistic regression analysis, high levels of P. gingivalis and T. forsythia were associated with sites that failed to respond to treatment compared with sites that did respond. This is in agreement with some findings in a study by Kinney et al. 7 Consequently, by adding the levels of these species into the biomarker profile of the three GCF enzymes, the predictive power for treatment outcome was raised from 80% to >92%. Therefore, it should be stressed that the present study findings strongly indicate that high levels of the three enzymes, supplemented by high levels of P. gingivalis and T. forsythia, at initial assessment predict poor outcome for those sites when conventional treatment is used. Thus, knowledge of the total combined profile of these biomarkers at patient assessment provides information that is useful in directing treatment.
To validate the predictive value of this biomarker profile, threshold values determined here were tested against the clinical data of an independent cohort of 22 patients. These patients have been described previously by Gul et al., 12 but only GCF enzyme data were available for these patients; therefore, validation was only possible against the three enzyme biomarkers. Enzyme threshold points determined here maintained high levels of sensitivity and specificity for predicting the outcome of treatment, proving that they are reliable in different sample cohorts. However, further testing is required, particularly in cohorts of challenging patients, for example, those with diabetes mellitus.
There are some limitations to the study in addition to those mentioned earlier; however, despite these the study not only stands alone but also presents novel aspects and avenues for research and diagnosis of periodontal disease. The power calculation indicated an ideal study population of 100 would be required, but although some patient dropout (12/ 101) was encountered, it was calculated early on in the study that levels of Fusobacterium and a lack of difference in responses between DB and NB sites essentially made them redundant variables; thus, this study was adequately powered. In addition, it was found that BOP was too variable a measure given its subjective nature, and so a more rigorous primary outcome measure of ‡2-mm improvement in PD was used, which is accepted as being outside interexaminer variability. 11 Examining all sites in a patient would be the ultimate aim given the site-specific nature of CP, but this was not feasible in this study due to patient numbers and time required. However, finding that data from the patient cohort in this study match that from an independent study group provides strong validation and confidence in the present study findings. Finally, it would be of great interest to examine the relationship among the chosen biomarkers and disease onset, transition from gingivitis to periodontitis, or whether a site is undergoing active destruction, all avenues that further studies should explore to improve prognosis and guide treatment.
CONCLUSIONS
This study shows that knowledge of the levels of three GCF enzymes plus two bacterial species at a site comprises a unique biomarker profile or fingerprint that is useful for predicting the outcome of periodontal treatment. This is important because one of the most common decisions that periodontists must make is whether to provide rigorous treatment, such as surgery plus systemic antibiotic therapy, or whether to limit treatment to more conservative measures (scaling and root surface debridement). Although clearly taking this study data forward to produce a chairside test is challenging, the data indicate that this is an avenue worth pursuing and that this biomarker profiling might aid in treatment regimen decision making and thus improve patient outcomes for this chronic, hard-to-treat but large global disease burden.
